Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC (revusiran) in healthy volunteer subjects.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01814839
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date March 2013
Completion date May 2015

See also
  Status Clinical Trial Phase
Completed NCT02292186 - A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis Phase 2
Completed NCT01961921 - The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) Phase 2
Completed NCT01960348 - APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Phase 3
Completed NCT01617967 - Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis Phase 2
Completed NCT01559077 - Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects Phase 1
Completed NCT01981837 - Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis Phase 2
Approved for marketing NCT02939820 - Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)